Drugs / BMS-986226
last change Dec 2021 re-read 2 minutes ago

BMS-986226

Developed for
cancer
Investigated by
Bristol-Myers Squibb

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03251924 Sep 2017 → Dec 2021 cancer Bristol-Myers Squibb Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BMS-986226 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03251924
Route Intravenous “administered intravenously” NCT03251924